Melanie Schmidmeier

Lophius Biosciences GmbH develops and markets T-cell-based diagnostic test systems. The firm specializes in the development of products for the diagnosis and immuno monitoring of virus-specific immune responses. It also provides customized services in the field of cell-based bioactivity, as well as quality tests for pharmaceutical active substances. The firm focuses on improving therapy control and personalized treatment of patients in the area of transplantation medicine and infectious and autoimmune diseases. The company was founded by Ludwig Deml and Fritz Schwarzmann in 2002 and it is headquartered in Regensburg, Germany.

Lophius Biosciences GmbH develops and markets T-cell-based diagnostic test systems. The firm specializes in the development of products for the diagnosis and immuno monitoring of virus-specific immune responses. It also provides customized services in the field of cell-based bioactivity, as well as quality tests for pharmaceutical active substances. The firm focuses on improving therapy control and personalized treatment of patients in the area of transplantation medicine and infectious and autoimmune diseases. The company was founded by Ludwig Deml and Fritz Schwarzmann in 2002 and it is headquartered in Regensburg, Germany.

Lophius Biosciences GmbH develops and markets T-cell-based diagnostic test systems. The firm specializes in the development of products for the diagnosis and immuno monitoring of virus-specific immune responses. It also provides customized services in the field of cell-based bioactivity, as well as quality tests for pharmaceutical active substances. The firm focuses on improving therapy control and personalized treatment of patients in the area of transplantation medicine and infectious and autoimmune diseases. The company was founded by Ludwig Deml and Fritz Schwarzmann in 2002 and it is headquartered in Regensburg, Germany.